Re: Padeliporfin Vascular-Targeted Photodynamic Therapy versus Active Surveillance in Men with Low-Risk Prostate Cancer (CLIN1001 PCM301): An Open-Label, Phase 3, Randomised Controlled Trial

Samir S. Taneja

doi:10.1016/j.juro.2017.05.029

Re: Padeliporfin Vascular-Targeted Photodynamic Therapy versus Active Surveillance in Men with Low-Risk Prostate Cancer (CLIN1001 PCM301): An Open-Label, Phase 3, Randomised Controlled Trial

Samir S. Taneja

Biomedical Engineering

Research output: Contribution to journal › Comment/debate › peer-review

Original language	English (US)
Pages (from-to)	255-257
Number of pages	3
Journal	The Journal of urology
Volume	198
Issue number	2
DOIs	https://doi.org/10.1016/j.juro.2017.05.029
State	Published - Aug 1 2017

ASJC Scopus subject areas

Urology

Access to Document

10.1016/j.juro.2017.05.029

Cite this

@article{b1648e9576784fe7a66c7015860e67f0,

title = "Re: Padeliporfin Vascular-Targeted Photodynamic Therapy versus Active Surveillance in Men with Low-Risk Prostate Cancer (CLIN1001 PCM301): An Open-Label, Phase 3, Randomised Controlled Trial",

author = "Taneja, {Samir S.}",

year = "2017",

month = aug,

day = "1",

doi = "10.1016/j.juro.2017.05.029",

language = "English (US)",

volume = "198",

pages = "255--257",

journal = "The Journal of urology",

issn = "0022-5347",

publisher = "Elsevier Inc.",

number = "2",

}

TY - JOUR

T1 - Re

T2 - Padeliporfin Vascular-Targeted Photodynamic Therapy versus Active Surveillance in Men with Low-Risk Prostate Cancer (CLIN1001 PCM301): An Open-Label, Phase 3, Randomised Controlled Trial

AU - Taneja, Samir S.

PY - 2017/8/1

Y1 - 2017/8/1

UR - http://www.scopus.com/inward/record.url?scp=85056344182&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85056344182&partnerID=8YFLogxK

U2 - 10.1016/j.juro.2017.05.029

DO - 10.1016/j.juro.2017.05.029

M3 - Comment/debate

C2 - 29370650

AN - SCOPUS:85056344182

SN - 0022-5347

VL - 198

SP - 255

EP - 257

JO - The Journal of urology

JF - The Journal of urology

IS - 2

ER -

Re: Padeliporfin Vascular-Targeted Photodynamic Therapy versus Active Surveillance in Men with Low-Risk Prostate Cancer (CLIN1001 PCM301): An Open-Label, Phase 3, Randomised Controlled Trial

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this